| Literature DB >> 28818332 |
Matheus Thomaz Nogueira Silva Lima1, Larissa Batista Dos Santos1, Rafael Wesley Bastos2, Jacques Robert Nicoli2, Jacqueline Aparecida Takahashi3.
Abstract
Major health challenges as the increasing number of cases of infections by antibiotic multiresistant microorganisms and cases of Alzheimer's disease have led to searching new control drugs. The present study aims to verify a new way of obtaining bioactive extracts from filamentous fungi with potential antimicrobial and acetylcholinesterase inhibitory activities, using epigenetic modulation to promote the expression of genes commonly silenced. For such finality, five filamentous fungal species (Talaromyces funiculosus, Talaromyces islandicus, Talaromyces minioluteus, Talaromyces pinophilus, Penicillium janthinellum) were grown or not with DNA methyltransferases inhibitors (procainamide or hydralazine) and/or a histone deacetylase inhibitor (suberohydroxamic acid). Extracts from T. islandicus cultured or not with hydralazine inhibited Listeria monocytogenes growth in 57.66±5.98% and 15.38±1.99%, respectively. Increment in inhibition of acetylcholinesterase activity was observed for the extract from P. janthinellum grown with procainamide (100%), when compared to the control extract (39.62±3.76%). Similarly, inhibition of acetylcholinesterase activity increased from 20.91±3.90% (control) to 92.20±3.72% when the tested extract was obtained from T. pinophilus under a combination of suberohydroxamic acid and procainamide. Concluding, increases in antimicrobial activity and acetylcholinesterase inhibition were observed when fungal extracts in the presence of DNA methyltransferases and/or histone deacetylase modulators were tested.Entities:
Keywords: Acetylcholinesterase inhibition; Antimicrobial activity; Epigenetic modulation; Penicillium sp.; Talaromyces sp.
Mesh:
Substances:
Year: 2017 PMID: 28818332 PMCID: PMC5790575 DOI: 10.1016/j.bjm.2017.06.004
Source DB: PubMed Journal: Braz J Microbiol ISSN: 1517-8382 Impact factor: 2.476
Fig. 1(i) Metabolic profile after individual epigenetic modulation SA, suberohydroxamic acid; H, hydralazine; P, procainamide. (A) T. islandicus; (B) P. janthinellum; (C) T. minioluteus; (D) T. funiculosus; (E) T. pinophilus. (ii) Metabolic profile after combined epigenetic modulation SA, suberohydroxamic acid. H, hydralazine; P, procainamide. (F) T. islandicus; (G) P. janthinellum; (H) T. minioluteus; (I) T. funiculosus; (J) T. pinophilus.
Effect of the extracts obtained from the treatments with SA, P and H, alone or in combination, over L. monocytogenes growth (%).
| Species | Treatment | |||||
|---|---|---|---|---|---|---|
| Control | P | H | SA + P | SA + H | P + H | |
| Inhibition (%) | ||||||
| 15.38 ± 1.99c | – | 57.66 ± 5.98a | 39.54 ± 5.17b | 35.53 ± 4.89b | 36.73 ± 3.07b | |
| 32.67 ± 2.11a | 36.97 ± 5.22a | – | 32.191 ± 2.40a | 30.52 ± 1.50a | 39.50 ± 4.97a | |
| 32.48 ± 2.94ab | 28.89 ± 1.87b | – | 28.61 ± 1.58b | 30.14 ± 1.29ab | 36.73 ± 4.14a | |
| 31.10 ± 2.36bc | – | 29.90 ± 1.22c | – | 35.82 ± 1.53b | 41.55 ± 2.15a | |
| 29.52 ± 3.36a | 17.72 ± 3.56b | 23.40 ± 0.79ab | 29.52 ± 3.51a | – | – | |
Control, absence of epigenetic modulators; SA, suberohydroxamic acid; P, procainamide; H, hydralazine. Test control: ampicilin, 95.03% ± 0.59 of inhibition. –, not analyzed. Extract concentration, 200 μg mL−1. Different superscripts in a row differ significantly (p < 0.05).
Acetylcholinesterase inhibition activity of the extracts prepared using epigenetic modulators (%).
| Species | Treatment | |||||
|---|---|---|---|---|---|---|
| Control | P | H | SA + P | SA + H | P + H | |
| Inhibition (%) | ||||||
| 56.78 ± 5.07a | – | 68.04 ± 5.49a | 54.60 ± 5.47a | 69.90 ± 1.10a | 54.29 ± 5.05a | |
| 39.62 ± 3.76b | 100a | – | 0 | 54.13 ± 5.04b | 100a | |
| 100a | 100a | – | 100a | 100a | 100a | |
| 67.84 ± 1.89b | – | 92.79 ± 1.68a | – | 74.91 ± 5.04ab | 88.46 ± 4.55ab | |
| 20.91 ± 3.90c | 46.99 ± 1.77b | 83.30 ± 0.40a | 92.20 ± 3.72a | – | – | |
Control, absence of epigenetic modulators; SA, suberohydroxamic acid; P, procainamide; H, hydralazine. Test control, eserine 94.47 ± 2.45 of inhibition. –, not analyzed. Different superscripts in a row differ significantly (p < 0.05).
Fig. 2Epigenetic modulation of chromatin structure prone to increase gene transcription rate. (A) Euchromatin, more compact; (B) epigenetic modulation; (C) hetereochromatin, more transcribed genes. Higher proportion of acetylation/methylation.